Open AccessStandard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial
Author(s) -
Suzette Delaloge,
Martine Piccart,
Emiel J. Rutgers,
Saskia Litière,
Laura J. van ˈt Veer,
Franchette van den Berkmortel,
Étienne Brain,
Aleksandra Dudek-Perić,
Miguel Gil-Gil,
P Gómez,
Florentine Hilbers,
Zaman Khalil,
Susan Knox,
Sherko Küemmel,
G. Kunz,
A. Lesur,
JeanYves Pierga,
Peter M. Ravdin,
Isabel T. Rubio,
Mahasti Saghatchian,
Tineke J. Smilde,
Alastair Thompson,
Giuseppe Viale,
Gabriele Zoppoli,
Peter Vuylsteke,
Konstantinos Tryfonidis,
Coralie Poncet,
Jan Bogaerts,
Fátima Cardoso
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01371
Subject(s) - medicine , docetaxel , capecitabine , anthracycline , hazard ratio , breast cancer , regimen , oncology , clinical endpoint , fluorouracil , chemotherapy , confidence interval , cancer , gastroenterology , surgery , clinical trial , colorectal cancer
MINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen.